読み込み中
JPXHealthcareDrug Manufacturers - Specialty & Generic
最新データ
￥3,145
−￥25.00 · -0.79%
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
最新データ
￥3,145
−￥25.00 · -0.79%
日中の時刻はJSTです。市場データは遅延する場合があります。
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
日中レンジ
現在 ￥3,145
52週レンジ
現在 ￥3,145
日中の時刻はJSTです。市場データは遅延する場合があります。
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
日中レンジ
現在 ￥3,145
52週レンジ
現在 ￥3,145
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
NEXT FUNDS TOPIX Exchange Traded Fund1306.T23.56億0.01%35.17兆 JPY0.05%￥431.3-0.28%
iShares Core TOPIX ETF1475.T1.88億0.01%3.01兆 JPY0.05%￥425-0.21%
Vanguard Total International Stock ETFVXUS648.78万0.00%6657億 USD0.05%$84.54+0.12%
Vanguard FTSE Developed Markets ETFVEA429.22万0.00%3238億 USD0.03%$70.06+0.16%
iShares Core MSCI EAFE ETFIEFA261.39万0.00%1889.44億 USD0.07%$96.64+0.48%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS171.35万0.01%145億 USD0.06%$154.25+0.07%
iShares MSCI EAFE Small-Cap ETFSCZ139.95万0.01%128.31億 USD0.40%$83.95+0.39%
iShares Core MSCI Total International Stock ETFIXUS121.69万0.00%583.37億 USD0.07%$94.66+0.10%NEXT FUNDS TOPIX Exchange Traded Fund1306.TiShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares MSCI EAFE Small-Cap ETFSCZiShares Core MSCI Total International Stock ETFIXUSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
